scendea's profile picture. Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry.

Scendea

@scendea

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry.

Last week, Scendea had the pleasure of attending The UniSC's 10-year Anniversary Clinical Trials Conference in QLD, Australia. - Book a meeting with our award-winning team, and discover how we can support your #clinicaltrials in Australia: scendea.com/contact

scendea's tweet image. Last week, Scendea had the pleasure of attending The UniSC's 10-year Anniversary Clinical Trials Conference in QLD, Australia.
-
Book a meeting with our award-winning team, and discover how we can support your #clinicaltrials in Australia: scendea.com/contact

Read and download our latest Whitepaper, "Reference Product Sourcing and Regulatory Planning for Biotech Products", written in collaboration with Acnos Pharma - scendea.com/articles/refer… - Read and download the paper, today: - #whitepaper #drugdevelopment

scendea's tweet image. Read and download our latest Whitepaper, "Reference Product Sourcing and Regulatory Planning for Biotech Products", written in collaboration with Acnos Pharma - scendea.com/articles/refer…
-
Read and download the paper, today: 
-
#whitepaper #drugdevelopment
scendea's tweet image. Read and download our latest Whitepaper, "Reference Product Sourcing and Regulatory Planning for Biotech Products", written in collaboration with Acnos Pharma - scendea.com/articles/refer…
-
Read and download the paper, today: 
-
#whitepaper #drugdevelopment
scendea's tweet image. Read and download our latest Whitepaper, "Reference Product Sourcing and Regulatory Planning for Biotech Products", written in collaboration with Acnos Pharma - scendea.com/articles/refer…
-
Read and download the paper, today: 
-
#whitepaper #drugdevelopment
scendea's tweet image. Read and download our latest Whitepaper, "Reference Product Sourcing and Regulatory Planning for Biotech Products", written in collaboration with Acnos Pharma - scendea.com/articles/refer…
-
Read and download the paper, today: 
-
#whitepaper #drugdevelopment

The @US_FDA has announced a pilot program designed to streamline communication with sponsors following formal meetings. Discover how Scendea can support your FDA interactions, book a meeting with our team, today: scendea.com/contact - #FDAinteractionsupport #drugdevelopment

scendea's tweet image. The @US_FDA has announced a pilot program designed to streamline communication with sponsors following formal meetings. Discover how Scendea can support your FDA interactions, book a meeting with our team, today: scendea.com/contact
-
#FDAinteractionsupport #drugdevelopment
scendea's tweet image. The @US_FDA has announced a pilot program designed to streamline communication with sponsors following formal meetings. Discover how Scendea can support your FDA interactions, book a meeting with our team, today: scendea.com/contact
-
#FDAinteractionsupport #drugdevelopment
scendea's tweet image. The @US_FDA has announced a pilot program designed to streamline communication with sponsors following formal meetings. Discover how Scendea can support your FDA interactions, book a meeting with our team, today: scendea.com/contact
-
#FDAinteractionsupport #drugdevelopment
scendea's tweet image. The @US_FDA has announced a pilot program designed to streamline communication with sponsors following formal meetings. Discover how Scendea can support your FDA interactions, book a meeting with our team, today: scendea.com/contact
-
#FDAinteractionsupport #drugdevelopment

This November, Scendea had the pleasure of attending BIO-Europe Autumn 2025 in Vienna, Austria. Read the full article now, and get in touch to discuss your 2026 product development and regulatory needs with the team: scendea.com/articles/bio-e… - #drugdevelopment #regulatorystrategy

scendea's tweet image. This November, Scendea had the pleasure of attending BIO-Europe Autumn 2025 in Vienna, Austria. Read the full article now, and get in touch to discuss your 2026 product development and regulatory needs with the team: scendea.com/articles/bio-e…
-
#drugdevelopment #regulatorystrategy

The @EMA_News has updated its Clinical Trials in Human Medicines overview to add a new section on Scientific advice for public health emergencies and threats. - Book a consultation with Scendea’s experts today: scendea.com/contact - #drugdevelopment #regulatoryaffairs

scendea's tweet image. The @EMA_News has updated its Clinical Trials in Human Medicines overview to add a new section on Scientific advice for public health emergencies and threats.
-
Book a consultation with Scendea’s experts today: scendea.com/contact
-
#drugdevelopment #regulatoryaffairs
scendea's tweet image. The @EMA_News has updated its Clinical Trials in Human Medicines overview to add a new section on Scientific advice for public health emergencies and threats.
-
Book a consultation with Scendea’s experts today: scendea.com/contact
-
#drugdevelopment #regulatoryaffairs
scendea's tweet image. The @EMA_News has updated its Clinical Trials in Human Medicines overview to add a new section on Scientific advice for public health emergencies and threats.
-
Book a consultation with Scendea’s experts today: scendea.com/contact
-
#drugdevelopment #regulatoryaffairs
scendea's tweet image. The @EMA_News has updated its Clinical Trials in Human Medicines overview to add a new section on Scientific advice for public health emergencies and threats.
-
Book a consultation with Scendea’s experts today: scendea.com/contact
-
#drugdevelopment #regulatoryaffairs

Scendea's Director, Paul Cronin, and Regional BD Manager, Daniel Berg, are travelling across Australia next month, meeting with new and established clients. Explore #Scendea's services and discover how we can support your #medicinal #product development: scendea.com/services

scendea's tweet image. Scendea's Director, Paul Cronin, and Regional BD Manager, Daniel Berg, are travelling across Australia next month, meeting with new and established clients. 

Explore #Scendea's services and discover how we can support your #medicinal #product development: scendea.com/services

Are you attending the British Neuroscience Association's Festive Symposium? Scendea are delighted to be attending this coming December. Discover how our experts can support your product development journey. Get in touch to book a meeting: scendea.com/contact #FestiveSymposium

scendea's tweet image. Are you attending the British Neuroscience Association's Festive Symposium? Scendea are delighted to be attending this coming December. Discover how our experts can support your product development journey. Get in touch to book a meeting: scendea.com/contact
#FestiveSymposium

The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible. - For more information on this guidance, get in touch: scendea.com/contact

scendea's tweet image. The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible.
-
For more information on this guidance, get in touch: scendea.com/contact
scendea's tweet image. The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible.
-
For more information on this guidance, get in touch: scendea.com/contact
scendea's tweet image. The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible.
-
For more information on this guidance, get in touch: scendea.com/contact
scendea's tweet image. The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible.
-
For more information on this guidance, get in touch: scendea.com/contact

Read and download our latest Whitepaper, "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", authored by Dr Dmitry Zamoryakhin, Scendea's Principal Medical Consultant: scendea.com/articles/consi… - #whitepaper

scendea's tweet image. Read and download our latest Whitepaper, "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", authored by Dr Dmitry Zamoryakhin, Scendea's Principal Medical Consultant: scendea.com/articles/consi…
-
#whitepaper

The @MHRAgovuk has updated its Early Access to Medicines Scheme (EAMS) Overview guidance to revise the “Dates for submission, Day 1 and Day 45” table. - For UK regulatory support, get in touch: scendea.com/contact - #drugdevelopment #earlyaccesstomedicines #MHRA

scendea's tweet image. The @MHRAgovuk has updated its Early Access to Medicines Scheme (EAMS) Overview guidance to revise the “Dates for submission, Day 1 and Day 45” table.
-
For UK regulatory support, get in touch: scendea.com/contact
-
#drugdevelopment #earlyaccesstomedicines #MHRA
scendea's tweet image. The @MHRAgovuk has updated its Early Access to Medicines Scheme (EAMS) Overview guidance to revise the “Dates for submission, Day 1 and Day 45” table.
-
For UK regulatory support, get in touch: scendea.com/contact
-
#drugdevelopment #earlyaccesstomedicines #MHRA
scendea's tweet image. The @MHRAgovuk has updated its Early Access to Medicines Scheme (EAMS) Overview guidance to revise the “Dates for submission, Day 1 and Day 45” table.
-
For UK regulatory support, get in touch: scendea.com/contact
-
#drugdevelopment #earlyaccesstomedicines #MHRA
scendea's tweet image. The @MHRAgovuk has updated its Early Access to Medicines Scheme (EAMS) Overview guidance to revise the “Dates for submission, Day 1 and Day 45” table.
-
For UK regulatory support, get in touch: scendea.com/contact
-
#drugdevelopment #earlyaccesstomedicines #MHRA

Yesterday, Scendea had the pleasure of attending the Dutch Life Sciences Conference. Discover how Scendea can support your EU product development and regulatory activities. Get in touch to speak to a member of the team: scendea.com/contact - #EUbiotechevents

scendea's tweet image. Yesterday, Scendea had the pleasure of attending the Dutch Life Sciences Conference. Discover how Scendea can support your EU product development and regulatory activities. Get in touch to speak to a member of the team: scendea.com/contact
-
#EUbiotechevents
scendea's tweet image. Yesterday, Scendea had the pleasure of attending the Dutch Life Sciences Conference. Discover how Scendea can support your EU product development and regulatory activities. Get in touch to speak to a member of the team: scendea.com/contact
-
#EUbiotechevents
scendea's tweet image. Yesterday, Scendea had the pleasure of attending the Dutch Life Sciences Conference. Discover how Scendea can support your EU product development and regulatory activities. Get in touch to speak to a member of the team: scendea.com/contact
-
#EUbiotechevents

Scendea are delighted to be attending Genesis 2025, this December! Secure a meeting with our experts, and discover how Scendea can support your global regulatory and product development strategy: scendea.com/contact - #Genesis #DrugDevelopment #UKbiotechsupport

scendea's tweet image. Scendea are delighted to be attending Genesis 2025, this December! Secure a meeting with our experts, and discover how Scendea can support your global regulatory and product development strategy: scendea.com/contact
-
#Genesis #DrugDevelopment #UKbiotechsupport

The @US_FDA has announced the “plausible mechanism” approval pathway for certain personalised rare disease treatments. - Read our new whitepaper to discover how the RDEP could accelerate your path to approval: scendea.com/articles/fdas-… - #whitepaper #drugdevelopment #RDEP

scendea's tweet image. The @US_FDA has announced the “plausible mechanism” approval pathway for certain personalised rare disease treatments. 
-
Read our new whitepaper to discover how the RDEP could accelerate your path to approval: scendea.com/articles/fdas-…
-
#whitepaper #drugdevelopment #RDEP
scendea's tweet image. The @US_FDA has announced the “plausible mechanism” approval pathway for certain personalised rare disease treatments. 
-
Read our new whitepaper to discover how the RDEP could accelerate your path to approval: scendea.com/articles/fdas-…
-
#whitepaper #drugdevelopment #RDEP
scendea's tweet image. The @US_FDA has announced the “plausible mechanism” approval pathway for certain personalised rare disease treatments. 
-
Read our new whitepaper to discover how the RDEP could accelerate your path to approval: scendea.com/articles/fdas-…
-
#whitepaper #drugdevelopment #RDEP
scendea's tweet image. The @US_FDA has announced the “plausible mechanism” approval pathway for certain personalised rare disease treatments. 
-
Read our new whitepaper to discover how the RDEP could accelerate your path to approval: scendea.com/articles/fdas-…
-
#whitepaper #drugdevelopment #RDEP

The @US_FDA has released the final guidance on how to prepare a Pre-Request for Designation (Pre-RFD). Get in touch to speak with a member of our team: scendea.com/contact - #preRFD #FDAagencyinteractions

scendea's tweet image. The @US_FDA has released the final guidance on how to prepare a Pre-Request for Designation (Pre-RFD). Get in touch to speak with a member of our team: scendea.com/contact
-
#preRFD #FDAagencyinteractions
scendea's tweet image. The @US_FDA has released the final guidance on how to prepare a Pre-Request for Designation (Pre-RFD). Get in touch to speak with a member of our team: scendea.com/contact
-
#preRFD #FDAagencyinteractions
scendea's tweet image. The @US_FDA has released the final guidance on how to prepare a Pre-Request for Designation (Pre-RFD). Get in touch to speak with a member of our team: scendea.com/contact
-
#preRFD #FDAagencyinteractions
scendea's tweet image. The @US_FDA has released the final guidance on how to prepare a Pre-Request for Designation (Pre-RFD). Get in touch to speak with a member of our team: scendea.com/contact
-
#preRFD #FDAagencyinteractions

Scendea are delighted to be sponsoring and attending BIO Partnering at JPM Week this coming January! - Schedule a meeting by searching 'Scendea' in the Partnering system or contact us today: scendea.com/contact - #BIOJPM #partnering #regulatoryaffairs #drugdevelopment

scendea's tweet image. Scendea are delighted to be sponsoring and attending BIO Partnering at JPM Week this coming January! 
-
Schedule a meeting by searching 'Scendea' in the Partnering system or contact us today: scendea.com/contact
- 
#BIOJPM #partnering #regulatoryaffairs #drugdevelopment

The EMA has published a draft guideline on the non-inferiority and equivalence comparisons in clinical trials. For support with your EU regulatory activities, get in touch to speak to Scendea's experts Scendea.com/contact

scendea's tweet image. The EMA has published a draft guideline on the non-inferiority and equivalence comparisons in clinical trials. For support with your EU regulatory activities, get in touch to speak to Scendea's experts Scendea.com/contact
scendea's tweet image. The EMA has published a draft guideline on the non-inferiority and equivalence comparisons in clinical trials. For support with your EU regulatory activities, get in touch to speak to Scendea's experts Scendea.com/contact
scendea's tweet image. The EMA has published a draft guideline on the non-inferiority and equivalence comparisons in clinical trials. For support with your EU regulatory activities, get in touch to speak to Scendea's experts Scendea.com/contact
scendea's tweet image. The EMA has published a draft guideline on the non-inferiority and equivalence comparisons in clinical trials. For support with your EU regulatory activities, get in touch to speak to Scendea's experts Scendea.com/contact

Scendea's Deputy Chief Medical Officer & Principal Medical Consultant, Dr Maria Beatrice Panico, and Business Development Consultant, Al Mills, are having an excellent time attending LSX Investival Showcase today! - #LSXInvestival #NetworkingEvent #HealthcareInnovation

scendea's tweet image. Scendea's Deputy Chief Medical Officer & Principal Medical Consultant, Dr Maria Beatrice Panico, and Business Development Consultant, Al Mills, are having an excellent time attending LSX Investival Showcase today!
-
#LSXInvestival #NetworkingEvent #HealthcareInnovation
scendea's tweet image. Scendea's Deputy Chief Medical Officer & Principal Medical Consultant, Dr Maria Beatrice Panico, and Business Development Consultant, Al Mills, are having an excellent time attending LSX Investival Showcase today!
-
#LSXInvestival #NetworkingEvent #HealthcareInnovation
scendea's tweet image. Scendea's Deputy Chief Medical Officer & Principal Medical Consultant, Dr Maria Beatrice Panico, and Business Development Consultant, Al Mills, are having an excellent time attending LSX Investival Showcase today!
-
#LSXInvestival #NetworkingEvent #HealthcareInnovation

The @MHRAgovuk has released a policy paper on rare therapies and regulatory considerations. Meet our team of experts and book an introductory call today: scendea.com/contact - #RareDiseaseTherapies #drugdevelopment #UKregulatoryconsiderations

scendea's tweet image. The @MHRAgovuk has released a policy paper on rare therapies and regulatory considerations. Meet our team of experts and book an introductory call today: scendea.com/contact
-
#RareDiseaseTherapies #drugdevelopment #UKregulatoryconsiderations
scendea's tweet image. The @MHRAgovuk has released a policy paper on rare therapies and regulatory considerations. Meet our team of experts and book an introductory call today: scendea.com/contact
-
#RareDiseaseTherapies #drugdevelopment #UKregulatoryconsiderations
scendea's tweet image. The @MHRAgovuk has released a policy paper on rare therapies and regulatory considerations. Meet our team of experts and book an introductory call today: scendea.com/contact
-
#RareDiseaseTherapies #drugdevelopment #UKregulatoryconsiderations
scendea's tweet image. The @MHRAgovuk has released a policy paper on rare therapies and regulatory considerations. Meet our team of experts and book an introductory call today: scendea.com/contact
-
#RareDiseaseTherapies #drugdevelopment #UKregulatoryconsiderations

Meet the author from our latest Whitepaper: "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", Dr Dmitry Zamoryakhin: scendea.com/articles/consi… - #whitepaper #drugdevelopment #CARTtherapies #FDAguidancerecomentations

scendea's tweet image. Meet the author from our latest Whitepaper: "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", Dr Dmitry Zamoryakhin: scendea.com/articles/consi…
-
#whitepaper #drugdevelopment #CARTtherapies #FDAguidancerecomentations
scendea's tweet image. Meet the author from our latest Whitepaper: "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", Dr Dmitry Zamoryakhin: scendea.com/articles/consi…
-
#whitepaper #drugdevelopment #CARTtherapies #FDAguidancerecomentations
scendea's tweet image. Meet the author from our latest Whitepaper: "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", Dr Dmitry Zamoryakhin: scendea.com/articles/consi…
-
#whitepaper #drugdevelopment #CARTtherapies #FDAguidancerecomentations
scendea's tweet image. Meet the author from our latest Whitepaper: "Insights on the FDA’s 2024 Guidance: Considerations for the Development of CAR-T Cell Products", Dr Dmitry Zamoryakhin: scendea.com/articles/consi…
-
#whitepaper #drugdevelopment #CARTtherapies #FDAguidancerecomentations

Are you attending the Dutch Life Sciences Conference? With 1 week to go, now is the perfect opportunity to book a meeting with Scendea and discover how we can support your #drugdevelopment journey! - Get in touch to book a meeting: scendea.com/contact - #DutchLifeScience

scendea's tweet image. Are you attending the Dutch Life Sciences Conference? With 1 week to go, now is the perfect opportunity to book a meeting with Scendea and discover how we can support your #drugdevelopment journey!
-
Get in touch to book a meeting: scendea.com/contact
-
#DutchLifeScience

Loading...

Something went wrong.


Something went wrong.